These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 26046389)

  • 1. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
    Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
    Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells.
    Ozawa H; Ranaweera RS; Izumchenko E; Makarev E; Zhavoronkov A; Fertig EJ; Howard JD; Markovic A; Bedi A; Ravi R; Perez J; Le QT; Kong CS; Jordan RC; Wang H; Kang H; Quon H; Sidransky D; Chung CH
    Clin Cancer Res; 2017 Sep; 23(17):5162-5175. PubMed ID: 28522603
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
    Hatakeyama H; Cheng H; Wirth P; Counsell A; Marcrom SR; Wood CB; Pohlmann PR; Gilbert J; Murphy B; Yarbrough WG; Wheeler DL; Harari PM; Guo Y; Shyr Y; Slebos RJ; Chung CH
    PLoS One; 2010 Sep; 5(9):e12702. PubMed ID: 20856931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β-catenin expression.
    Umbreit C; Flanjak J; Weiss C; Erben P; Aderhold C; Faber A; Stern-Straeter J; Hoermann K; Schultz JD
    Anticancer Res; 2014 Dec; 34(12):7061-9. PubMed ID: 25503133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
    Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
    Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
    Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
    [No Abstract]   [Full Text] [Related]  

  • 8. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
    Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
    J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5'-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells.
    Shi E; Wu Z; Karaoglan BS; Schwenk-Zieger S; Kranz G; Abdul Razak N; Reichel CA; Canis M; Baumeister P; Zeidler R; Gires O
    J Biomed Sci; 2023 Aug; 30(1):72. PubMed ID: 37620936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer.
    Obayashi M; Yoshida M; Tsunematsu T; Ogawa I; Sasahira T; Kuniyasu H; Imoto I; Abiko Y; Xu D; Fukunaga S; Tahara H; Kudo Y; Nagao T; Takata T
    Oncotarget; 2016 Feb; 7(7):8223-39. PubMed ID: 26882562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer.
    Schmitz S; Bindea G; Albu RI; Mlecnik B; Machiels JP
    Oncotarget; 2015 Oct; 6(33):34288-99. PubMed ID: 26437222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.
    Pollock NI; Wang L; Wallweber G; Gooding WE; Huang W; Chenna A; Winslow J; Sen M; DeGrave KA; Li H; Zeng Y; Grandis JR
    Clin Cancer Res; 2015 Oct; 21(20):4597-606. PubMed ID: 26138066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
    Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
    BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
    Vermorken JB; Psyrri A; Mesía R; Peyrade F; Beier F; de Blas B; Celik I; Licitra L
    Ann Oncol; 2014 Apr; 25(4):801-807. PubMed ID: 24577117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-34a regulates epithelial-mesenchymal transition and cancer stem cell phenotype of head and neck squamous cell carcinoma in vitro.
    Sun Z; Hu W; Xu J; Kaufmann AM; Albers AE
    Int J Oncol; 2015 Oct; 47(4):1339-50. PubMed ID: 26323460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling.
    Wu Q; Zhao Y; Wang P
    Biomed Pharmacother; 2018 Mar; 99():278-285. PubMed ID: 29353201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.